Company news

ImmunityBio, Inc. news in 2021

ImmunityBio, Inc.'s news releases, calls and decks from 2021, newest first.

View company

ImmunityBio Announces Completion of $470 Million Post-merger Financing to Fund Late-stage Cancer Clinical Trials, Phase 3 of COVID T-Cell Universal Boost Vaccine Trial and Provides Update on Bladder Cancer BLA Filing

December 19, 2021

ImmunityBio Expands Vaccine Program to Accelerate Use of “Mix-and-Match” Technologies in Developing and Manufacturing Next-Generation COVID-19 Vaccines

November 17, 2021

ImmunityBio to Present at the Jefferies London Healthcare Conference

November 3, 2021

ImmunityBio Announces Primary Endpoint Met in a Second Indication in Bladder Cancer Trial with 57% Disease-Free Survival in Patients with BCG Unresponsive Papillary Disease

October 18, 2021

ImmunityBio Completes Enrollment in Phase 2 Study of Nant Cancer Vaccine for 3rd Line or Greater Metastatic Pancreatic Cancer Patients—90% of Patients Have Exceeded Historical Survival Rates to Date

October 12, 2021

National Cancer Institute Selects ImmunityBio’s N-803 IL-15 Receptor Agonist to Combine with Keytruda in 700-Site Lung-MAP Clinical Trial of a Chemo-Free Therapy

October 3, 2021

ImmunityBio Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with a Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-free in Phase 2/3 Trial

September 12, 2021

ImmunityBio Builds Commercial Team with the Appointment of Seasoned Marketing and Reimbursement Executives

September 6, 2021

ImmunityBio Announces Oral Presentation of Phase 2/3 Clinical Trial Results of Patients with BCG-Unresponsive Bladder Cancer Carcinoma at the Upcoming American Urological Association’s Annual Meeting

August 31, 2021

ImmunityBio Appoints Dr. Patrick Soon-Shiong to Global Chief Scientific and Medical Officer; Newly Created Role Will Lead Company’s Scientific Strategy and Global Expansion

August 15, 2021

CytRx Comments on Quarterly Results and Recent Strategic Initiatives

August 11, 2021

ImmunityBio’s Novel Immunotherapy NANT Cancer Vaccine Currently Being Studied in Multiple Clinical Trials Is Awarded a U.S. Patent

July 26, 2021

ImmunityBio Announces Authorization to Proceed with Phase 1/2/3 Randomized Trial in South Africa of Their Dual-Antigen T-Cell Vaccine as a Universal Boost in Previously Vaccinated Participants Against COVID-19

July 13, 2021

ImmunityBio and NantOmics Announce Clinical Validation of a Proprietary Method to Identify Unique Targets for Immunotherapy in Individual Breast Cancer Patients

June 27, 2021

Motus GI Appoints Experienced Financial Biotech Executive, Sonja Nelson, to its Board of Directors and as Chair of Audit Committee

June 22, 2021

FDA Authorizes ImmunityBio Study of Anktiva and PD-L1 t-haNK to Increase Effectiveness of Trodelvy in Triple-Negative Breast Cancer

June 14, 2021

ImmunityBio Announces HIV Clinical Pipeline with Opening of a Phase 1 ‘HIV Cure Study’ in Patients Off Therapy and a Phase 2 Study in Acutely Infected Patients

June 9, 2021

ImmunityBio Expands Trials of T-Cell-Based COVID-19 Vaccine Candidate as a ‘Universal Boost’ in Vaccinated Subjects and Receives Approval to Test Intranasal Spray in South Africa

May 24, 2021

ImmunityBio to Present at the Jefferies 2021 Virtual Healthcare Conference

May 23, 2021

ImmunityBio to Present Preliminary Phase 2 Data of 68% Durable Disease Control with Anktiva Plus Checkpoint Inhibitor in First 140 Patients Enrolled with Lung Cancer and Multiple Tumor Types Who Failed Prior Checkpoint Therapy at ASCO 2021

May 19, 2021

FDA Authorizes ImmunityBio to Conduct a Trial of its First-in-Human, Cryopreserved, Memory Cytokine-Enriched NK Cell (m-ceNK) Platform in Solid Tumors

May 16, 2021

CytRx Comments on Quarterly Results and Year-to-Date Progress

May 12, 2021

ImmunityBio Announces 78 Percent Complete Response Following Chemotherapy-Free Combination of IL-15 Superagonist Anktiva with Rituxan in Relapsed Non-Hodgkin Lymphoma Patients

May 3, 2021

ImmunityBio Announces Launch of Phase 2 Trial of IL-15 Superagonist Anktiva With Antiretroviral Therapy to Inhibit HIV Reservoirs

April 28, 2021

ImmunityBio Announces 100th Patient Dosed with Proprietary Natural Killer Cells; NK Trials Cover Multiple Indications

April 21, 2021

ImmunityBio Announces Single Prime hAd5 COVID-19 Vaccination Induces a 10-Fold Increase in T Cell Response Equivalent to T Cell Responses from Patients Previously Infected with SARS-CoV-2

April 7, 2021

ImmunityBio Appoints Dr. Linda Maxwell and CEO Richard Adcock to Board of Directors

March 31, 2021

ImmunityBio Announces 12-Month Overall Survival Probability of 83% in NCI-Led Phase 1 Study of Multi-Targeted hAd5 Immunotherapy Vaccine in Patients with Advanced Metastatic Prostate Cancer

March 28, 2021

ImmunityBio Announces NIH-Led Research Affirming that PD-L1 T-haNK Therapy Overcomes T-Cell Escape in Multiple Types of Resistant Tumors

March 21, 2021

ImmunityBio Announces Positive Interim Phase I Safety Data of hAd5 T-Cell COVID-19 Vaccine Candidate in Oral and Sublingual Formulations

March 14, 2021

ImmunityBio Announces Novel ACE2 Decoy COVID-19 Therapeutic that Shows High Binding to SARS-CoV-2 Variants and Neutralizes Live Viruses

March 10, 2021

ImmunityBio and NantKwest Complete Merger

March 8, 2021

Stockholders of NantKwest Approve Merger With ImmunityBio

March 7, 2021

ImmunityBio and NantKwest Begin Dosing Participants in Global Trials for Novel COVID-19 Vaccine; Subcutaneous Route in South Africa, Oral and Sublingual in the U.S.

March 7, 2021

ImmunityBio Appoints John Brennan and Wesley Clark to Board of Directors

February 23, 2021

All Three Independent Proxy Advisory Firms – ISS, Glass Lewis and Egan-Jones – Recommend NantKwest Stockholders Vote “FOR” the Pending Merger With ImmunityBio

February 23, 2021

ImmunityBio Announces ASCO Genitourinary Cancer Symposium Presentation of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 71% Complete Response Rate

February 15, 2021

ImmunityBio and NantKwest Announce FDA Authorization to Study hAd5 T-Cell COVID-19 Vaccine for Combination of Subcutaneous, Oral and Sublingual Boost to Induce T-Cell, Mucosal, and Antibody Immunity

February 10, 2021

ImmunityBio Announces Positive Phase 2 Results Showing That Anktiva Restores the Activity of Checkpoint Inhibitors in Patients Who Have Relapsed Checkpoint Immunotherapy in Non-Small Cell Lung Cancer

January 27, 2021

NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials

January 12, 2021

NantKwest Executive Chairman Dr. Patrick Soon-Shiong to Present at 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021

January 5, 2021

Decks in 2021